Exploring the in situ expression of vascular endothelial growth factor and endoglin in pemphigus foliaceus variants and pemphigus vulgaris

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author MIYAMOTO, D. FMUSP-HC
MARUTA, C. W. FMUSP-HC
SANTI, C. G. FMUSP-HC
ZOROQUIAIN, P.
DIAS, A. B. T.
MANSURE, J. J.
BURNIER JR., M. N.
AOKI, V. FMUSP-HC
dc.date.issued 2018
dc.identifier.citation JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, v.32, n.11, p.1954-1958, 2018
dc.identifier.issn 0926-9959
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/29903
dc.description.abstract Background Erythroderma is a severe manifestation of pemphigus foliaceus (PF), a blistering disease mediated by IgG autoantibodies against desmoglein 1. Increasing evidence supports the contribution of angiogenic mediators in the pathogenesis of erythroderma. ObjectiveMethodsTo evaluate the in situ expression of vascular endothelial growth factor (VEGF) and endoglin in patients with PF with erythroderma. Formalin-fixed paraffin-embedded skin samples obtained from patients with erythrodermic PF (n = 19; 12 patients with endemic PF), non-erythrodermic PF (n = 17), pemphigus vulgaris (PV; n = 10), psoriasis (n = 10) and healthy individuals (HI; n = 10) were processed in an automated immunohistochemistry platform utilizing anti-VEGF and anti-endoglin as primary antibodies. Reactivity was evaluated both manually (0 = negative; 1+ = mild; 2+ = intense) and through an automated microvessel analysis algorithm. ResultsConclusionVascular endothelial growth factor expression in erythrodermic PF was higher than in non-erythrodermic PF (P = 0.034) and in HI (P = 0.004), and similar to psoriasis (P = 0.667) and PV (P = 0.667). In non-erythrodermic PF, VEGF positivity was similar to HI (P = 0.247), and lower than psoriasis (P = 0.049) and PV (P = 0.049). Both erythrodermic and non-erythrodermic PF presented similar endoglin expression (P = 0.700). In addition, endoglin positivity during erythrodermic PF was similar to psoriasis (P = 0.133) and lower than PV (P = 0.0009). Increased expression of in situVEGF suggests that healing processes are triggered in response to tissue damage led by autoantibodies in PF, especially during erythroderma. Reduced endoglin positivity suggests that an unbalanced angiogenesis may occur during erythrodermic PF. Further studies may help to confirm if the regulation of VEGF and endoglin expression in patients with PF can contribute to control the healing process and enable disease remission. Overexpression of VEGF in erythrodermic PF as well as in PV and psoriasis points out a dysregulated repair process in severe forms of these diseases and suggests VEGF and endoglin could act as prognostic markers and future therapeutic targets to enable proper healing in PF.
dc.description.sponsorship · FUNADERSP
dc.language.iso eng
dc.publisher WILEY
dc.relation.ispartof Journal of the European Academy of Dermatology and Venereology
dc.rights restrictedAccess
dc.subject.other erythroderma; regeneration; repair; skin
dc.title Exploring the in situ expression of vascular endothelial growth factor and endoglin in pemphigus foliaceus variants and pemphigus vulgaris
dc.type article
dc.rights.holder Copyright WILEY
dc.description.group LIM/56
dc.identifier.doi 10.1111/jdv.14903
dc.identifier.pmid 29489039
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author MIYAMOTO, D.:HC:ICHC
hcfmusp.author MARUTA, C. W.:FM:MDT
hcfmusp.author SANTI, C. G.:HC:ICHC
hcfmusp.author AOKI, V.:FM:MDT
hcfmusp.author.external · ZOROQUIAIN, P.:McGill Univ, Ocular Pathol Lab, MUHC, Montreal, PQ, Canada
· DIAS, A. B. T.:McGill Univ, Ocular Pathol Lab, MUHC, Montreal, PQ, Canada
· MANSURE, J. J.:McGill Univ, Dept Urol, Montreal, PQ, Canada
· BURNIER JR., M. N.:McGill Univ, Ocular Pathol Lab, MUHC, Montreal, PQ, Canada
hcfmusp.origem.id WOS:000448786400040
hcfmusp.origem.id 2-s2.0-85044853032
hcfmusp.publisher.city HOBOKEN
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Ameglio F, 1997, J BIOL REG HOMEOS AG, V11, P148
· Aoki V, 2015, J DERMATOL, V42, P18, DOI 10.1111/1346-8138.12675
· Bae ON, 2015, BIOMOL THER, V23, P12, DOI 10.4062/biomolther.2014.102
· Bielefeld KA, 2013, CELL MOL LIFE SCI, V70, P2059, DOI 10.1007/s00018-012-1152-9
· BROWN LF, 1995, J INVEST DERMATOL, V104, P744, DOI 10.1111/1523-1747.ep12606974
· Creamer D, 1996, LANCET, V348, P1101, DOI 10.1016/S0140-6736(05)64447-9
· Kumar I, 2009, BRIT J SURG, V96, P1484, DOI 10.1002/bjs.6778
· Liu Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086273
· Martin P, 2015, BRIT J DERMATOL, V173, P370, DOI 10.1111/bjd.13954
· Miyamoto D, 2017, J EUR ACAD DERMATOL, V31, P333, DOI 10.1111/jdv.13905
· Miyamoto D, 2018, HUMAN PATHOLOGY CASE, V12, P1
· Perez-Gomez E, 2014, J INVEST DERMATOL, V134, P247, DOI 10.1038/jid.2013.263
· Valluru M, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00089
· Van de Kerkhof PCM, 1998, ACTA DERM-VENEREOL, V78, P19
· Viac J, 1997, ARCH DERMATOL RES, V289, P158, DOI 10.1007/s004030050172
· Wise LM, 2012, CELL MICROBIOL, V14, P1376, DOI 10.1111/j.1462-5822.2012.01802.x
· Zheng ZF, 2017, WOUND REPAIR REGEN, V25, P389, DOI 10.1111/wrr.12546
dc.description.index MEDLINE
dc.identifier.eissn 1468-3083
hcfmusp.citation.scopus 2
hcfmusp.citation.wos 3
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country Canadá


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics